|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/343 | (2006.01) |
| A61K 9/00 | (2006.01) | ||
| A61K 47/02 | (2006.01) | ||
| A61K 31/4725 | (2006.01) | ||
| A61P 27/02 | (2006.01) |
| (11) | Number of the document | 2934510 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13865757.2 |
| Date of filing the European patent application | 2013-12-18 | |
| (97) | Date of publication of the European application | 2015-10-28 |
| (45) | Date of publication and mention of the grant of the patent | 2020-10-28 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2013/076041 |
| Date | 2013-12-18 |
| (87) | Number | WO 2014/100135 |
| Date | 2014-06-26 |
| (30) | Number | Date | Country code |
| 201261739609 P | 2012-12-19 | US | |
| 201361758147 P | 2013-01-29 | US |
| (72) |
NEWMAN, Mary, US
HUNKE, William, US
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | LFA-1 INHIBITOR FORMULATIONS |
| LFA-1 INHIBITOR FORMULATIONS |